跳转至内容
Merck
CN

SML0331

Prasugrel

≥98% (HPLC)

别名:

5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate, CS 747, CS-747, Effient, Efient, LY640315

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H20FNO3S
化学文摘社编号:
分子量:
373.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Prasugrel, ≥98% (HPLC)

InChI

1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3

SMILES string

CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C3CC3)c4ccccc4F

InChI key

DTGLZDAWLRGWQN-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: >5 mg/mL (warmed at 60 °C)

storage temp.

2-8°C

Quality Level

Gene Information

human ... P2RY12(64805)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

Prasugrel is a thienopyridine prodrug and is considered to be more potent than clopidogrel. It shows a faster generation and also reduces thrombotic events. Prasugrel is less dependent on the CYP (cytochrome P450) enzymes for its conversion to active metabolite.
Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors.
Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors. Prasugrel interacts in an irreversible manner with the residues Cys97 and Cys175 of the human P2Y12-receptor.

Features and Benefits

This compound is featured on the P2 Receptors: P2Y G-Protein Family page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Matti K Itkonen et al.
Clinical pharmacology and therapeutics, 104(3), 495-504 (2017-11-25)
The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we investigated the effects of two widely used P2Y12 inhibitors on montelukast pharmacokinetics. Clopidogrel (300 mg on day
Antonio Tello-Montoliu et al.
Platelets, 27(8), 777-783 (2016-06-04)
Everolimus-eluting bioabsorbable scaffolds (BVSs) have exhibited similar long-term clinical outcomes compared to its everolimus-eluting metallic counterparts. However, reports from earlier studies have shown a signal for an increased rate of stent thrombosis. The aim of the current investigation is to
Juan F Iglesias et al.
Lancet (London, England), 394(10205), 1243-1253 (2019-09-07)
Newer-generation drug-eluting stents that combine ultrathin strut metallic platforms with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) compared with contemporary thin strut second-generation drug-eluting stents.
Shigeru Saito et al.
Circulation journal : official journal of the Japanese Circulation Society, 78(7), 1684-1692 (2014-04-25)
Prasugrel is an antiplatelet agent that shows more prompt, potent, and consistent platelet inhibition than clopidogrel. The objective of this study was to confirm the efficacy and safety of prasugrel at loading/maintenance doses of 20/3.75 mg. Japanese patients (n=1,363) with
D Venetsanos et al.
European heart journal. Acute cardiovascular care, 2048872618803760-2048872618803760 (2018-10-24)
Our aim was to study the impact of sex on anticoagulant treatment outcomes during percutaneous coronary intervention in acute myocardial infarction patients. This study was a prespecified analysis of the Bivalirudin versus Heparin in ST-Segment and Non ST-Segment Elevation Myocardial

商品

Surface receptors for extracellular nucleotides are called P2 receptors. Learn more about P2Y G protein-coupled receptors, GPCRs, and ionotropic P2 receptors (P2X ligand-gated ion channels, LGICs).

胞外核苷酸表面受体又称P2受体。了解更多有关 P2Y G 蛋白偶联受体、GPCR 和离子型 P2 受体(P2X 配体门控离子通道,LGIC)的信息。

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持